{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-25-000037","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.058679+00:00","generated_at":"2026-05-27T02:00:52.019547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue","bullets":["Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).","Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.","2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.","Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.","Board authorized $15B share repurchase program and 15% dividend increase."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-25-000037","json":"https://secwatch.observer/filing/0000059478-25-000037.json","markdown":"https://secwatch.observer/filing/0000059478-25-000037.md","text":"https://secwatch.observer/filing/0000059478-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/0000059478-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/lly-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:00:52.019547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}